Results 171 to 180 of about 36,274 (199)

Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection

MedComm, Volume 7, Issue 8, August 2026.
EOPC is a distinct clinicopathological entity separable from SOPC, differing fundamentally in genetic susceptibility, TMPRSS2:ERG fusion frequency, and survival outcomes. Although research remains nascent, this review provides the first comprehensive synthesis of current evidence, offering a critical foundation to guide future investigations into this ...
Xingyu Xiong, Weizhen Zhu, Weichao Huang, Shiyu Zhang, Qi Deng, Jie Yang, Hang Xu, Qiang Wei, Lu Yang   +8 more
wiley   +1 more source

Exploring the pharmacological mechanisms of resibufogenin in castration-resistant prostate cancer via network pharmacology and experimental validation. [PDF]

Front Oncol
Xing Y, Xiang L, Jia Y, Yang Y.
europepmc   +1 more source

Cardiovascular Diseases and Cancer: Convergent Proteostasis Networks at the Crossroads of Mechanisms and Therapeutic Opportunities

MedComm, Volume 7, Issue 8, August 2026.
The disruption of proteostasis, encompassing the ubiquitin–proteasome system, autophagy, UPR/ER stress, and chaperone function, represents a fundamental mechanism shared by both cancer and cardiovascular diseases. While these pathways frequently facilitate tumor progression, they are crucial for maintaining proteostasis in cardiac tissue. Consequently,
Jacob Eli García Torres, Norbert Frey, Ashraf Yusuf Rangrez   +2 more
wiley   +1 more source

Phase II Trial of Opaganib Addition in Metastatic Castration-Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide. [PDF]

Cancer Med
Brown JT, Nazha B, Ferreira AC, Armeson K, Hill EG, Ogretmen B, Mehrotra S, Brisendine A, Magrath G, Plasse TF, Gourdin TS, Kucuk O, Lilly M.   +12 more
europepmc   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer. [PDF]

Cancer Res
Kittane S, Ladewig E, Li T, Love JR, Blawski R, Gao Y, Arruabarrena-Aristorena A, Zhao P, Dalrymple SL, Liu H, Guo X, Sallaku M, Kelkar N, Garcia-Martinez L, Carmona Sanz J, Chen W, Stoudmann C, Baldino L, Razavi-Mohseni M, Kalemi I, Beer MA, Castel P, Brennen WN, Scaltriti M, Morey L, Cocco E, Ji H, Chan HM, Battle A, Leslie CS, Karthaus WR, Toska E.   +31 more
europepmc   +1 more source

Nucleotide Metabolism in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao, Yiyu Zeng, Yike Xu, Shu Rao, Mouna Khouchani, Hassna Soummane, Jingyi Li, Rui Liu   +7 more
wiley   +1 more source

Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone. [PDF]

Clin Case Rep
Une M, Yamamoto S, Fuse H, Fujiwara R, Yonese J, Noda K.   +5 more
europepmc   +1 more source

Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

The Prostate, Volume 86, Issue 11, Page 1187-1194, August 2026.
ABSTRACT Background Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Ondřej Fiala, Michaela Tkadlecová, Zuzana Váchalová, Milan Hora, Jan Králíček, Petr Stránský Jr., Václav Liška, Matteo Santoni, Giuseppe Luigi Banna, Kristýna Pivovarčíková, Ondřej Topolčan, Jindřich Fínek   +11 more
wiley   +1 more source